Cambridge, UK, October 22 2019: o2h discovery is pleased to announce a significant expansion in its existing Synthetic Chemistry collaboration with Sosei Heptares, an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities.
News
Exclusive deal with KSL Biomedical signals PredictImmune’s major move into North America
As well as investing and recruiting 25 graduates and school-leavers at its Cambridge office, Deloitte has also recently welcomed partner, Fran Cousins to the local Cambridge team.
James Veale, product manager at GiroNEX – a spin-out company from Innomech Group – has been named ‘Young Design Engineer of the Year’ at the 10th anniversary British Engineering Excellence Awards ceremony in London on Friday 11 October.
Westbury, NY – Oct. 16, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired PPA Research Group, Inc., a human hematologic product provider, based in Gray, TN. This acquisition will significantly expand BioIVT’s immunology and disease-state product portfolios, enhancing its ability to support immuno-oncology and cell therapy researchers.
The website for Integrated Biologix (www.ibiologix.com), a fully integrated non-clinical development consultancy for biotherapeutics goes live.
LOUGHBOROUGH, England (October 14, 2019) – Science World, the Fisher Scientific Laboratory Experience, made a successful debut at Leicester Tigers Rugby Club on 10 October. The event, hosted by Thermo Fisher Scientific, showcased the latest in laboratory innovations available through the Fisher Scientific channel. Thousands of products were available for attendees to experience, making it an ideal event for anyone working in or around a laboratory.
AMSBIO announces two new Luciferase assay kits designed to help you improve your gene reporter assays.
Cambridge, UK – 16 October, 2019 – Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that it has raised $56 million in a Series B financing round, led by one of Europe’s largest VC firms Atomico and joined by Intel Capital, Global Brain and btov Partners. All previous investors, including Balderton Capital, Amadeus Capital Partners, and Jonathan Milner also participated in the round.
Cambridge, UK, 14th October 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date. The funding will support internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest.